Evidence map›Paper›PMID 40965835›Full record

Trial reportEchocardiography (Mount Kisco, N.Y.)2025

Effect of Cardioprotection on the Right Ventricular Function in Breast Cancer Patients Receiving Potentially Cardiotoxic Therapy: A SAFE Trial Substudy.

Maria Riccarda Del Bene, Icro Meattini, Giuseppe Pilato, Carlotta Becherini, Francesca Martella, Viola Salvestrini, Livia Marrazzo, Calogero Saieva, Iacopo Olivotto, Giuseppe Barletta and 1 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Echocardiography (Mount Kisco, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria Riccarda Del BeneDiagnostic Cardiology, CardioThoracic and Vascular Department, Careggi University Hospital, Florence, Italy.
Icro MeattiniDepartment of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy.
Giuseppe PilatoDiagnostic Cardiology, CardioThoracic and Vascular Department, Careggi University Hospital, Florence, Italy.
Carlotta BecheriniRadiation Oncology and Breast Unit, Careggi University Hospital, Florence, Italy.
Francesca MartellaBreast and Medical Oncology Units, Oncology Department, Azienda USL Toscana Centro, Florence, Italy.
Viola SalvestriniRadiation Oncology and Breast Unit, Careggi University Hospital, Florence, Italy.
Livia MarrazzoDepartment of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy.
Calogero SaievaCancer Risk Factors and Lifestyle Epidemiology Unit, Institute For Cancer Research Prevention and Clinical Network (ISPRO), Florence, Italy.
Iacopo OlivottoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Giuseppe BarlettaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Lorenzo LiviDepartment of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy.

Funding

Fondazione Fiorenzo Fratini Onlus, IFCA Spa, Conad Società Cooperativa, Fabiani Gioiellerie, Permira, Rinascente, and Giorgio Tesi GroupFondazione Radioterapia Oncologica
6 · The paper itself

Abstract

purposeTo evaluate the effects of cardioprotective therapy (CPT) with neurohormonal inhibitors on cancer therapeutics-related cardiac dysfunction (CTRCD) in breast cancer patients, focusing on right ventricular (RV) function.

methodsThis is a secondary analysis of SAFE study, a randomized, phase 3, double-blind, placebo-controlled, four-arm trial, in which the effects of short-term CPT (bisoprolol, ramipril, or both) compared to placebo (P-arm) on subclinical CTRCD were evaluated in 222 women without cardiac risk factors who received intensive anthracycline-based chemotherapy (median isoequivalent doxorubicin dose 288 mg/m

resultsAt 24 months, LV CTRCD was observed in 42.9% of P-arm and 3.1% of the CPT arms (p < 0.001). Compared to the CPT arms, there was a significant reduction in RV FAC (-10.5%), S'-wave velocity (-12.2%), and tricuspid annular plane systolic excursion (-9.6%) in the P-arm. Additionally, the RV diameter increased by 7% in the P-arm. RV CTRCD was found in 49.2% of the P-arm and 22% of the CPT arms (p < 0.001).

conclusionShort-term neurohormonal cardioprotection was effective in reducing RV CTRCD.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCardiotonic AgentsCardiotoxicityVentricular Dysfunction, RightVentricular Function, RightAdultAgedBisoprololDouble-Blind MethodEchocardiographyFemaleHeart VentriclesHumansMiddle AgedRamiprilAntineoplastic AgentsBisoprololCardiotonic AgentsRamipril3D echocardiographyanthracyclinebreast cancerchemotherapy‐induced cardiotoxicityneurohormonal inhibitorsright ventricular function

Identifiers

PMID40965835
PMCPMC12445402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.